Get Involved
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Study Purpose
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | N/A - 30 Years |
| Gender | All |
Inclusion Criteria:
- - All patients must be diagnosed with neuroblastoma, and categorized as high risk at the time of diagnosis; exception: patients who are initially diagnosed as non-high-risk neuroblastoma, but later converted (and/or relapsed) to high risk neuroblastoma are also eligible.
- - All patients must have completed therapy including intensive induction followed by ASCT and radiotherapy to be eligible for ANBL0032; radiotherapy may be waived for patients who either have small adrenal masses which are completely resected up front, or who never have an identifiable primary tumor; examples of such therapies include: - Following treatment per A3973 protocol.
- - Following treatment per Pediatric Oncology Group (POG)-9341/9342 protocol.
- - Following treatment per CCG3891.
- - Following treatment on New Approaches to Neuroblastoma Therapy (NANT) 2001-02.
- - Enrollment on or following treatment per ANBL02P1.
- - Enrollment on or following treatment per ANBL07P1.
- - Tandem transplant patients are eligible: - Following treatment on or per ANBL0532.
- - Following treatment per POG 9640.
- - Following treatment per COG ANBL00P1.
- - Following treatment per CHP 594/Dana-Farber Cancer Institute (DFCI) 34-DAT.
- - No more than 12 months from the date of starting the first induction chemotherapy after diagnosis to the date of ASCT except for the rare occasions as noted below; for tandem ASCT patients, this will be the date of the FIRST stem cell infusion; exception: for those who are initially diagnosed as non-high risk neuroblastoma, but later converted (and/or relapsed) to high risk neuroblastoma, the 12 months restriction should start from the date of induction therapy for high risk neuroblastoma (not from the initial induction therapy for non-high risk disease), to the date of ASCT.
- - At pre-ASCT evaluation patients must meet the International Neuroblastoma Response Criteria (INRC) for CR, VGPR, or PR for primary site, soft tissue metastases and bone metastases; patients who meet those criteria must also meet the protocol specified criteria for bone marrow response as outlined below: - =< 10% tumor (of total nucleated cellular content) seen on any specimen from a bilateral bone marrow aspirate/biopsy.
- - Patient who have no tumor seen on the prior bone marrow, and then have =< 10% tumor on any of the bilateral marrow aspirate/biopsy specimens done at pre-ASCT and/or pre-enrollment evaluation will also be eligible (note that per INRC this would have been defined as "overall" response of progressive disease [PD]) - Prior to enrollment on ANBL0032, a determination of mandatory disease staging must be performed (tumor imaging studies including computed tomography [CT] or magnetic resonance imaging [MRI], MIBG scan, and vanillylmandelic acid [VMA]/homovanillic acid [HVA]; bone marrow aspirates are required but biopsy may be omitted if negative prior to ASCT); this disease assessment is required for eligibility and should be done preferably within 2 weeks, but must be done within a maximum of 4 weeks before enrollment.
- - For those with residual disease before radiotherapy, re-evaluation of irradiated residual tumors is preferably performed at the earliest 5 days after completing radiotherapy; patients with residual disease are eligible; biopsy is not required; patients who have biopsy proven residual disease after ASCT will be enrolled on Stratum 07.
- - Patients must not have progressive disease at the time of study enrollment except for protocol specified bone marrow response and except for elevations of catecholamines as the only sign of disease in a patient who had normal catecholamines at pre-ASCT evaluation.
- - Patients must be enrolled before treatment begins; the date protocol therapy is projected to start must be no later than ten (10) calendar days after the date of study enrollment; patients should be enrolled preferably between day 56 and day 85 after peripheral blood stem cell (PBSC) infusion (day from 2nd stem cell infusion for tandem transplant); patients must be enrolled no later than day 200 after PBSC infusion; enrollment must occur after completion of radiotherapy, and after completion of tumor assessment post-ASCT and radiotherapy; informed consent should be obtained within 3 weeks pre-ASCT up to the time of registration.
- - Patients must not have received prior anti-disialoganglioside (GD2) antibody therapy.
- - Patients must have a Lansky or Karnofsky performance scale score of >= 50% and patients must have a life expectancy of >= 2 months.
- - Total absolute phagocyte count (APC = %neutrophils + %monocytes) X white blood cell (WBC) is at least 1000/uL.
- - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows: - No greater than 0.4 mg/dL (1 month to < 6 months) - No greater than 0.5 mg/dL (6 months to < 1 year) - No greater than 0.6 mg/dL (1 to < 2 years) - No greater than 0.8 mg/dL (2 to < 6 years) - No greater than 1.0 mg/dL (6 to < 10 years) - No greater than 1.2 mg/dL (10 to < 13 years) - No greater than 1.4 mg/dL (>= 13 years [female]) - No greater than 1.5 mg/dL (13 to < 16 years [male]) - No greater than 1.7 mg/dL (>= 16 years [male]) - Total bilirubin =< 1.5 x normal.
- - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x normal.
- - Veno-occlusive disease, if present, should be stable or improving.
- - Shortening fraction of >= 27% by echocardiogram, or if shortening fraction abnormal, ejection fraction of >= 55% by gated radionuclide study or echocardiogram; note: the echocardiogram or gated radionuclide study must be performed within 4 weeks prior to enrollment.
- - Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) > 60% predicted by pulmonary function test; for children who are unable to do pulmonary function tests (PFTs), no evidence of dyspnea at rest and no exercise intolerance should be documented; note: the pulmonary function test must be performed within 4 weeks prior to enrollment.
- - Patients with seizure disorder may be enrolled if on anticonvulsants and well-controlled; central nervous system (CNS) toxicity < grade 2.
- - Written informed consent in accordance with institutional and Food and Drug Administration (FDA) guidelines must be obtained from parent or legal guardian.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT00026312 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Alice L Yu |
| Principal Investigator Affiliation | Children's Oncology Group |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH |
| Overall Status | Active, not recruiting |
| Countries | Australia, Canada, New Zealand, Puerto Rico, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma |
PRIMARY OBJECTIVES:
- I. Determine if monoclonal antibody Ch14.18 (dinutuximab) + cytokines + isotretinoin (13-cis-retinoic acid, or RA) improves event free survival after myeloablative therapy and stem cell rescue as compared to RA alone, in high risk neuroblastoma patients who have achieved a pre-autologous stem cell transplant (ASCT) response of complete response (CR), very good partial response (VGPR), or partial response (PR).
- I. Determine if monoclonal antibody Ch14.18 + cytokines + isotretinoin (13-cis-retinoic acid, or RA) improves overall survival after myeloablative therapy and stem cell rescue as compared to RA alone, in high risk neuroblastoma patients who have achieved a pre-ASCT response of CR, VGPR, or PR.
- II. Determine if immunotherapy + RA improves event free survival and overall survival as compared to RA alone, in the subgroup of high risk International Neuroblastoma Staging System (INSS) stage 4 neuroblastoma patients who have achieved a pre-ASCT response of CR, VGPR, or PR.
- III. Determine the toxicities of the combination of monoclonal antibody Ch14.18 with cytokines.
- IV. To compare the outcome data of the patients with persistent disease documented by biopsy (Stratum 07) to the historical data for the analogous patients from Children's Cancer Group (CCG)-3981.
- V. To further describe and refine the event free survival (EFS) and overall survival (OS) estimates and baseline characteristics for subjects receiving Ch14.18 + cytokines + RA, following cessation of the randomized portion of the study.
- VI. To further describe the safety and toxicity of Ch14.18 + cytokines + RA under the new administration guidelines implemented following cessation of the randomized portion of the study with focus on: a) number of courses delivered per subject; b) number of dose reductions or stoppage (ch14.18 and/or interleukin [IL]-2); and c) number of toxic deaths.
- I. In the subgroup of neuroblastoma patients who have achieved a pre-ASCT response of CR, VGPR, or PR, determine if there is a difference between the two randomized regimens in reducing the minimal residual disease (MRD) burden as detected by the following parameters: meta-iodobenylguanidine (MIBG) scan, immunocytology (IC) of blood and bone marrow samples, reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase, phosphoglycolate phosphatase (PGP) 9.5, and melanoma antigen family A, 1 (MAGE-1) in blood and bone marrow.
- II. Determine if change from baseline of MRD is associated with event free and overall survival.
- III. Determine whether tumor biology at diagnosis correlates with event-free and overall survival, for either of the randomized regimens.
- IV. To explore the relationship between antibody-dependent cellular cytoxicity (ADCC) and EFS.
- V. To determine a descriptive profile of human anti-chimeric antibody (HACA) during immunotherapy.
- VI. To determine the variability of 13-cis-retinoic-acid pharmacokinetics and relationship to pharmacogenomic parameters and determine if these levels and/or genetic variations correlate with EFS or systemic toxicity.
- VII. To determine the potential effect of ch14.18 on cardiac repolarization and to evaluate ch14.18 plasma levels.
- VIII. To determine if the presence of naturally occurring anti-glycan antibodies correlates with allergic reactions and blood levels of ch14.18.
- IX. To determine if the genotype of Fc receptor (FcR) and killer cell immunoglobulin-like receptor (Kir)/Kir-ligand correlate with EFS.
- X. To determine if natural killer cell p30-related protein (NKp30) isoform expression and single nucleotide polymorphism (SNP), and circulating ligand B7-H6 are prognostic of EFS or OS.
- II. Patients in the first set of strata are randomized to 1 of 2 treatment arms.
Arms
Active Comparator: Arm I (isotretinoin) (closed to accrual as of 4/16/2009)
Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive isotretinoin PO BID for 14 days. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may cross over to Arm II provided they have not experienced disease progression and have not received any further anti-neuroblastoma therapy following completion of isotretinoin therapy.
Experimental: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)
Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive immunotherapy comprising sargramostim SC or IV over 2 hours on days 0-13 during courses 1, 3, and 5 and dinutuximab IV over 10-20 hours on days 3-6 of courses 1-5. Patients also receive aldesleukin IV continuously on days 0-3 and 7-10 during courses 2 and 4. Immunotherapy repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive isotretinoin as in Arm I beginning on day 11 of immunotherapy.
Interventions
Biological: - Aldesleukin
Given IV
Biological: - Dinutuximab
Given IV
Drug: - Isotretinoin
Given PO
Other: - Laboratory Biomarker Analysis
Correlative studies
Other: - Pharmacological Study
Correlative studies
Other: - Quality-of-Life Assessment
Ancillary studies
Biological: - Sargramostim
Given IV or SC
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Children's Hospital of Alabama
Birmingham, Alabama, 35233
Status
Address
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Status
Address
Providence Alaska Medical Center
Anchorage, Alaska, 99508
Status
Address
Phoenix Childrens Hospital
Phoenix, Arizona, 85016
Status
Address
Banner University Medical Center - Tucson
Tucson, Arizona, 85719
Status
Address
Arkansas Children's Hospital
Little Rock, Arkansas, 72202-3591
Status
Address
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Status
Address
Kaiser Permanente Downey Medical Center
Downey, California, 90242
Status
Address
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Status
Address
Loma Linda University Medical Center
Loma Linda, California, 92354
Status
Address
Miller Children's and Women's Hospital Long Beach
Long Beach, California, 90806
Status
Address
Children's Hospital Los Angeles
Los Angeles, California, 90027
Status
Address
Valley Children's Hospital
Madera, California, 93636
Status
Address
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609
Status
Address
Kaiser Permanente-Oakland
Oakland, California, 94611
Status
Address
Children's Hospital of Orange County
Orange, California, 92868
Status
Address
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304
Status
Address
Sutter Medical Center Sacramento
Sacramento, California, 95816
Status
Address
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817
Status
Address
Rady Children's Hospital - San Diego
San Diego, California, 92123
Status
Address
UCSF Medical Center-Parnassus
San Francisco, California, 94143
Status
Address
UCSF Medical Center-Mission Bay
San Francisco, California, 94158
Status
Address
Children's Hospital Colorado
Aurora, Colorado, 80045
Status
Address
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado, 80218
Status
Address
Connecticut Children's Medical Center
Hartford, Connecticut, 06106
Status
Address
Yale University
New Haven, Connecticut, 06520
Status
Address
Alfred I duPont Hospital for Children
Wilmington, Delaware, 19803
Status
Address
MedStar Georgetown University Hospital
Washington, District of Columbia, 20007
Status
Address
Children's National Medical Center
Washington, District of Columbia, 20010
Status
Address
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Status
Address
Lee Memorial Health System
Fort Myers, Florida, 33901
Status
Address
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida, 33908
Status
Address
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
Status
Address
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Status
Address
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida, 32207
Status
Address
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Status
Address
Nicklaus Children's Hospital
Miami, Florida, 33155
Status
Address
Miami Cancer Institute
Miami, Florida, 33176
Status
Address
AdventHealth Orlando
Orlando, Florida, 32803
Status
Address
Arnold Palmer Hospital for Children
Orlando, Florida, 32806
Status
Address
Nemours Children's Clinic - Orlando
Orlando, Florida, 32806
Status
Address
Orlando Health Cancer Institute
Orlando, Florida, 32806
Status
Address
Nemours Children's Hospital
Orlando, Florida, 32827
Status
Address
Nemours Children's Clinic - Pensacola
Pensacola, Florida, 32504
Status
Address
Johns Hopkins All Children's Hospital
Saint Petersburg, Florida, 33701
Status
Address
Saint Joseph's Hospital/Children's Hospital-Tampa
Tampa, Florida, 33607
Status
Address
Saint Mary's Medical Center
West Palm Beach, Florida, 33407
Status
Address
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, 30329
Status
Address
Augusta University Medical Center
Augusta, Georgia, 30912
Status
Address
Memorial Health University Medical Center
Savannah, Georgia, 31404
Status
Address
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Status
Address
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Status
Address
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Status
Address
Lurie Children's Hospital-Chicago
Chicago, Illinois, 60611
Status
Address
University of Illinois
Chicago, Illinois, 60612
Status
Address
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Status
Address
Advocate Children's Hospital-Oak Lawn
Oak Lawn, Illinois, 60453
Status
Address
Saint Jude Midwest Affiliate
Peoria, Illinois, 61637
Status
Address
Southern Illinois University School of Medicine
Springfield, Illinois, 62702
Status
Address
Riley Hospital for Children
Indianapolis, Indiana, 46202
Status
Address
Ascension Saint Vincent Indianapolis Hospital
Indianapolis, Indiana, 46260
Status
Address
Blank Children's Hospital
Des Moines, Iowa, 50309
Status
Address
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242
Status
Address
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Status
Address
Norton Children's Hospital
Louisville, Kentucky, 40202
Status
Address
Children's Hospital New Orleans
New Orleans, Louisiana, 70118
Status
Address
Maine Children's Cancer Program
Scarborough, Maine, 04074
Status
Address
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Status
Address
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Status
Address
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Status
Address
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
Status
Address
Tufts Children's Hospital
Boston, Massachusetts, 02111
Status
Address
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Status
Address
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Status
Address
Baystate Medical Center
Springfield, Massachusetts, 01199
Status
Address
C S Mott Children's Hospital
Ann Arbor, Michigan, 48109
Status
Address
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201
Status
Address
Henry Ford Health Saint John Hospital
Detroit, Michigan, 48236
Status
Address
Michigan State University Clinical Center
East Lansing, Michigan, 48824
Status
Address
Hurley Medical Center
Flint, Michigan, 48503
Status
Address
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
Grand Rapids, Michigan, 49503
Status
Address
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Status
Address
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota, 55404
Status
Address
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455
Status
Address
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Status
Address
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Status
Address
University of Missouri Children's Hospital
Columbia, Missouri, 65212
Status
Address
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, 64108
Status
Address
Cardinal Glennon Children's Medical Center
Saint Louis, Missouri, 63104
Status
Address
Washington University School of Medicine
Saint Louis, Missouri, 63110
Status
Address
Mercy Hospital Saint Louis
Saint Louis, Missouri, 63141
Status
Address
Children's Hospital and Medical Center of Omaha
Omaha, Nebraska, 68114
Status
Address
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Status
Address
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
Status
Address
Nevada Cancer Research Foundation NCORP
Las Vegas, Nevada, 89169
Status
Address
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756
Status
Address
Hackensack University Medical Center
Hackensack, New Jersey, 07601
Status
Address
Morristown Medical Center
Morristown, New Jersey, 07960
Status
Address
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901
Status
Address
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08903
Status
Address
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
Status
Address
Overlook Hospital
Summit, New Jersey, 07902
Status
Address
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Status
Address
Albany Medical Center
Albany, New York, 12208
Status
Address
Montefiore Medical Center - Moses Campus
Bronx, New York, 10467
Status
Address
Roswell Park Cancer Institute
Buffalo, New York, 14263
Status
Address
NYU Langone Hospital - Long Island
Mineola, New York, 11501
Status
Address
The Steven and Alexandra Cohen Children's Medical Center of New York
New Hyde Park, New York, 11040
Status
Address
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016
Status
Address
Mount Sinai Hospital
New York, New York, 10029
Status
Address
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Status
Address
University of Rochester
Rochester, New York, 14642
Status
Address
State University of New York Upstate Medical University
Syracuse, New York, 13210
Status
Address
New York Medical College
Valhalla, New York, 10595
Status
Address
Mission Hospital
Asheville, North Carolina, 28801
Status
Address
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Status
Address
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Status
Address
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Status
Address
Duke University Medical Center
Durham, North Carolina, 27710
Status
Address
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
Status
Address
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Status
Address
Children's Hospital Medical Center of Akron
Akron, Ohio, 44308
Status
Address
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Status
Address
Rainbow Babies and Childrens Hospital
Cleveland, Ohio, 44106
Status
Address
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Status
Address
Nationwide Children's Hospital
Columbus, Ohio, 43205
Status
Address
Dayton Children's Hospital
Dayton, Ohio, 45404
Status
Address
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo, Ohio, 43606
Status
Address
Mercy Children's Hospital
Toledo, Ohio, 43608
Status
Address
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Status
Address
Legacy Emanuel Children's Hospital
Portland, Oregon, 97227
Status
Address
Legacy Emanuel Hospital and Health Center
Portland, Oregon, 97227
Status
Address
Oregon Health and Science University
Portland, Oregon, 97239
Status
Address
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Status
Address
Geisinger Medical Center
Danville, Pennsylvania, 17822
Status
Address
Penn State Children's Hospital
Hershey, Pennsylvania, 17033
Status
Address
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Status
Address
Saint Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134
Status
Address
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224
Status
Address
Rhode Island Hospital
Providence, Rhode Island, 02903
Status
Address
Medical University of South Carolina
Charleston, South Carolina, 29425
Status
Address
Prisma Health Richland Hospital
Columbia, South Carolina, 29203
Status
Address
BI-LO Charities Children's Cancer Center
Greenville, South Carolina, 29605
Status
Address
Greenville Cancer Treatment Center
Greenville, South Carolina, 29605
Status
Address
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Status
Address
T C Thompson Children's Hospital
Chattanooga, Tennessee, 37403
Status
Address
East Tennessee Childrens Hospital
Knoxville, Tennessee, 37916
Status
Address
Saint Jude Children's Research Hospital
Memphis, Tennessee, 38105
Status
Address
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232
Status
Address
Dell Children's Medical Center of Central Texas
Austin, Texas, 78723
Status
Address
Driscoll Children's Hospital
Corpus Christi, Texas, 78411
Status
Address
Medical City Dallas Hospital
Dallas, Texas, 75230
Status
Address
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Status
Address
Cook Children's Medical Center
Fort Worth, Texas, 76104
Status
Address
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
Status
Address
Methodist Children's Hospital of South Texas
San Antonio, Texas, 78229
Status
Address
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
Status
Address
Primary Children's Hospital
Salt Lake City, Utah, 84113
Status
Address
University of Vermont and State Agricultural College
Burlington, Vermont, 05405
Status
Address
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Status
Address
Inova Fairfax Hospital
Falls Church, Virginia, 22042
Status
Address
Children's Hospital of The King's Daughters
Norfolk, Virginia, 23507
Status
Address
Naval Medical Center - Portsmouth
Portsmouth, Virginia, 23708-2197
Status
Address
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Status
Address
Carilion Children's
Roanoke, Virginia, 24014
Status
Address
Seattle Children's Hospital
Seattle, Washington, 98105
Status
Address
Providence Sacred Heart Medical Center and Children's Hospital
Spokane, Washington, 99204
Status
Address
West Virginia University Healthcare
Morgantown, West Virginia, 26506
Status
Address
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Status
Address
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792
Status
Address
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Status
Address
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, 53226
International Sites
Status
Address
John Hunter Children's Hospital
Hunter Regional Mail Centre, New South Wales, 2310
Status
Address
Sydney Children's Hospital
Randwick, New South Wales, 2031
Status
Address
The Children's Hospital at Westmead
Westmead, New South Wales, 2145
Status
Address
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029
Status
Address
Royal Children's Hospital-Brisbane
Herston, Queensland, 4029
Status
Address
Queensland Children's Hospital
South Brisbane, Queensland, 4101
Status
Address
Women's and Children's Hospital-Adelaide
North Adelaide, South Australia, 5006
Status
Address
Royal Children's Hospital
Parkville, Victoria, 3052
Status
Address
Princess Margaret Hospital for Children
Perth, Western Australia, 6008
Status
Address
Alberta Children's Hospital
Calgary, Alberta, T3B 6A8
Status
Address
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Status
Address
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
Status
Address
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
Status
Address
Janeway Child Health Centre
Saint John's, Newfoundland and Labrador, A1B 3V6
Status
Address
IWK Health Centre
Halifax, Nova Scotia, B3K 6R8
Status
Address
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, L8N 3Z5
Status
Address
Children's Hospital
London, Ontario, N6A 5W9
Status
Address
Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1
Status
Address
Hospital for Sick Children
Toronto, Ontario, M5G 1X8
Status
Address
The Montreal Children's Hospital of the MUHC
Montreal, Quebec, H3H 1P3
Status
Address
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5
Status
Address
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
Quebec, , G1V 4G2
Status
Address
Starship Children's Hospital
Grafton, Auckland, 1145
Status
Address
Christchurch Hospital
Christchurch, , 8011
Status
Address
San Jorge Children's Hospital
San Juan, , 00912
